| Document |
Document Title |
|
WO/2017/158621A1 |
The present invention provides novel compounds with improved solubility and altered pharmacokinetic properties. The compounds of the present invention may be represented by Formula (I).
|
|
WO/2017/160925A1 |
Disclosed herein are compounds of Formulae (I), and (II), methods of synthesizing compounds of Formulae (I) and (II), and methods of using compounds of Formulae (I) and (II) as an analgesic.
|
|
WO/2017/156270A1 |
N-(2-((2,3-difluorobenzyl)thio)-6-(((2R,3S)-3,4-dihydroxybut
an-2-yl)oxy)pyrimidin-4-yl)azetidine-1-sulfonamide (compound 3) and N-(6-(((2R,3S)-3,4-dihydroxy butan-2-yl)oxy)-2-((4-fluoro benzyl)thio)pyrimidin-4-yl)-3-methylazetidine-1-su...
|
|
WO/2017/148518A1 |
The invention relates to new benzonitrile derivatives of the formula (I) wherein R1 to R3 and A are as defined in the description and Claims, to their medicaments, to methods for their therapeutic use and to pharmaceutical compositions c...
|
|
WO/2017/143628A1 |
The present invention relates to a method for preparing an industrially-produced method for preparing a hypolipidemic drug Ezetimibe and an intermediate thereof.
|
|
WO/2017/140251A1 |
Provided are a method for preparing ezetimibe and an intermediate compound thereof. Provided is an economic method which is new, is easy to realize in industry, only includes very few steps and is established on a new intermediate. In th...
|
|
WO/2017/131221A1 |
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4a and R4b are as defined in the specification, processes for their preparation, pharmaceutical compositions cont...
|
|
WO/2017/131149A1 |
A compound shown by general formula (I-1) (in the formula, all symbols are as stated in the specification.) has selective S1P5 receptor-binding activity. Adjusting this activity makes it possible to obtain a therapeutic agent for S1P5-me...
|
|
WO/2017/120124A1 |
Described are deuterium-substituted azetidine compounds of Formula (I), which are modulators of sphingosine 1 -phosphate receptor. Also described are pharmaceutical compositions comprising the deuterium-substituted azetidine compounds, a...
|
|
WO/2017/117708A1 |
Provided herein are compounds of the formula I: as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing t...
|
|
WO/2017/116558A1 |
The present invention relates to compounds that inhibit LSD1 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and ...
|
|
WO/2017/111172A1 |
The present invention provides compounds represented by formula (I) as cationic lipids, or pharmaceutically-acceptable salts or the like thereof.
|
|
WO/2017/109095A1 |
The invention relates to (hetero) cyclic compounds as S1P modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment, alleviation or prevention of diseases or disorders mediated by an S1P receptor.
|
|
WO/2017/106064A1 |
The present invention relates to biaryl monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A1, Q, A2, M, W, RX and Rz are as defined herein. The present invention also relates to compositio...
|
|
WO/2017/097732A1 |
The invention relates to a compound of formula (I) wherein R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
|
|
WO/2017/080966A1 |
Described herein are tetrahydronaphthalene compounds with estrogen receptor modulation activity or function having the Formula (I) structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substi...
|
|
WO/2017/050990A1 |
The present invention relates to a compound with formula (I) or a salt and/or a pharmaceutically acceptable solvate thereof, the method for preparing same as well as the uses thereof, in particular the therapeutic use thereof, mainly in ...
|
|
WO/2017/045648A1 |
The present invention relates to the field of chemical synthesis, and specifically to a preparation method for a deuterated compound. The preparation method comprises: converting a non-deuterated compound at least containing one structur...
|
|
WO/2017/042233A1 |
The present application relates to novel azetidinimine of formula (I). Wherein R1-R6 are as defined in claim 1. The azetidinimine of the invention are useful as antibiotics and as inhibitors of a carbapenemases. The present invention thu...
|
|
WO/2017/040537A1 |
Disclosed herein are embodiments of a method of accelerating bone healing in a subject in need thereof, comprising administering to the subject a compound disclosed here. The method may further comprise selecting or identifying a subject...
|
|
WO/2017/010399A1 |
Provided are compounds having RORγt inhibitory effects represented by formula (I). Compounds represented by formula (I) (wherein L represents -NR1ACO-, -SO2- or the like, A represents a substituted or unsubstituted aromatic carbocyclic ...
|
|
WO/2017/005950A1 |
The invention relates to β-lactam derivative compounds, capable of blocking thermoreceptor activation, in particular TRPM8 channels, and to the uses thereof as therapeutic agents for treating diseases of the respiratory system (coughing...
|
|
WO/2017/006968A1 |
The present invention provides: a method for producing a 7H-pyrrolo[2, 3-d]pyrimidine derivative that is useful as a janus kinase (JAK) inhibitor; an intermediate of the 7H-pyrrolo[2, 3-d]pyrimidine derivative; and a method for producing...
|
|
WO/2017/004522A1 |
Provided herein are compounds and methods for inhibiting histone deacetylase ("HDAC") enzymes (e.g., HDAC1, HDAC2, and HDAC3).
|
|
WO/2016/198374A1 |
Substituted aromatic sulfonamides of formula (I) pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a di...
|
|
WO/2016/198691A1 |
The present invention relates to compounds of formula I or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein ASC is -N(R8)(R9)ASC-1 ASC-1 is Ring A represents a 4- to 6-membered saturated ring containing carbon atoms ...
|
|
WO/2016/185032A1 |
The present disclosure relates to certain novel compounds of Formula (I) and to their utility in modulation of levels of monoamines, dopamine, norepinephrine and serotonin, in cerebral cortical areas of the mammalian brain, and more spec...
|
|
WO/2016/172496A1 |
Provided are novel compounds of Formula (I) and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSDl. Also provided are pharmaceutical compositions ...
|
|
WO/2016/172424A1 |
Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: (I)
|
|
WO/2016/168058A1 |
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions con...
|
|
WO/2016/168056A1 |
This disclosure relates to the field of molecules having pesticidal utility against pests in Phyla Arthropoda, Mollusca, and Nematoda, processes to produce such molecules, intermediates used in such processes, pesticidal compositions con...
|
|
WO/2016/141279A1 |
Provided herein are small molecule inhibitors of maternal embryonic leucine zipper kinase (MELK) having the structure of formula (I), wherein X and R1-R3 are defined in the specification. The compounds are useful for treating cancer and ...
|
|
WO/2016/134292A1 |
Ester derivatives of sobetirome with enhanced CNS distribution are disclosed.
|
|
WO/2016/123707A1 |
The present application relates to a novel process for the preparation of difluoromethyl ether-based derivatives from, for example, aliphatic and aromatic hydroxyl precursors, compositions comprising these compounds and their use, in par...
|
|
WO/2016/124141A1 |
Disclosed are heterocyclic-substituted N-sulfonylbenzamide derivatives, a preparation method for the derivatives, and a pharmaceutical use of the derivatives. Specifically, disclosed are compounds of formula (II) or pharmaceutically acce...
|
|
WO/2016/124139A1 |
Disclosed are heterocyclic-substituted N-sulfonylbenzamide derivatives, a preparation method for the derivatives, and a pharmaceutical use of the derivatives. Specifically, disclosed are compounds of formula (I) or pharmaceutically accep...
|
|
WO/2016/123242A1 |
The invention provides compounds of formula I and II and salts thereof, wherein R1, R2, Y, R3, and R4 have any of the meanings described in the specification, as well as compositions comprising such compounds and salts, and methods for t...
|
|
WO/2016/105448A1 |
This disclosure provides compounds and compositions for use as analgesics and for the treatment of various conditions, such as pain, headaches, allodynia, and fibromyalgia. The disclosure also provides compounds that are ligands, and in ...
|
|
WO/2016/101887A1 |
The invention provides amides that inhibit cellular necrosis and/or human receptor interacting protein 1 kinase (RIP1), including corresponding sulfonamides, and pharmaceutically acceptable salts, hydrides and stereoisomers thereof. The ...
|
|
WO/2016/097071A1 |
Described herein are compounds that are estrogen receptor modulators of Formula (I) and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein SERMF is a selective estrogen receptor modulator fragment and with th...
|
|
WO/2016/088834A1 |
A compound shown by general formula (I) (in the formula, all of the symbols are as defined in the specification) has selective S1P5 receptor agonist activity due to having a linker from a phenyl group to a cyclic substituent in a dihydro...
|
|
WO/2016/073420A1 |
The invention provides a chemical entity of Formula (I) wherein R1, R2, R3, R4, X, and Y have any of the values described herein, and compositions comprising such chemical entities; methods of making them; and their use in a wide range o...
|
|
WO/2016/057322A1 |
Provided herein are deuterated compounds and compositions useful in increasing PPAR5 activity. The compounds and compositions provided herein are useful for the treatment of PPAR5 related diseases (e.g., muscular diseases, vascular disea...
|
|
WO/2016/040225A1 |
The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are GPR120 G protein-coupled receptor modulato...
|
|
WO/2016/034671A1 |
A compound of formula (la), (lb) or (lc) wherein: n is 1 or 2; RN is H or Me; R1 is optionally one or more halo or methyl groups; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2O...
|
|
WO/2016/030310A1 |
The present invention relates to a compound of formula I wherein R1 is hydrogen, methoxy or fluoro; R2/R2' are independently from each other hydrogen, methoxy or fluoro; R3/R4 are independently from each other hydrogen or halogen; R is h...
|
|
WO/2016/027757A1 |
The present invention addresses the problem of providing a novel compound for realizing an effect on a therapeutic and/or preventive drug for mental illnesses, such as depression, atypical depression, treatment-resistant depression, anxi...
|
|
WO/2016/011805A1 |
Provided is a marine oil-degrading bacterium, which is Alcanivorax dieselolei T6-6 and has a preservation number of CGMCC NO:9033. The bacterium can be used in degradation and clearance of petroleum hydrocarbon, environmental pollution c...
|
|
WO/2016/007534A1 |
The invention provides compounds having the general Formula (I); and pharmaceutically acceptable salts thereof; wherein the variables RA, RAA, subscript n, subscript q, ring A, X2, L, subscript m, X1, R1, R2, R3, R4, R5, D and E have the...
|
|
WO/2016/002753A1 |
The present invention provides a cationic lipid represented by formula (I) (in the formula, R1 and R2 are C8-24 alkyl groups or the like, R3 is a hydrogen atom, C1-3 alkyl group, formula (A) (in the formula, R4 and R5 are hydrogen atoms ...
|
